DEF: Pasithea Seeks Shareholder Approval for Major Stock Increase

Pasithea Therapeutics Corp. is calling a Special Meeting of Stockholders to vote on increasing authorized common stock by 400% and expanding its 2023 Stock Incentive Plan.

Summary

• A Special Meeting of Stockholders will be held virtually on January 28, 2026, at 9:00 AM Eastern Time.
• Stockholders will vote on two proposals: increasing authorized common stock from 100,000,000 to 500,000,000 shares, and increasing the shares available under the 2023 Stock Incentive Plan by 11,985,779 to a total of 14,000,000 shares.
• The increase in authorized common stock is sought to provide flexibility for future financings, acquisitions, strategic transactions, and stock splits, and to align with peer companies following a recent capital raise.
• The expansion of the 2023 Stock Incentive Plan is crucial for attracting, recruiting, motivating, and retaining high-quality talent, including a Chief Medical Officer, in a competitive industry where equity compensation is standard.
• As of the record date, December 22, 2025, there were 23,091,062 shares of Common Stock outstanding.
• The Board of Directors unanimously recommends voting FOR both proposals.

Sentiment

Score: 6

Explanation: The filing outlines necessary procedural steps for a growth-oriented biotech company, addressing capital flexibility and talent retention. While the proposals are logical for long-term strategic development, the significant potential for future shareholder dilution introduces a notable negative aspect, balancing the overall sentiment to moderately positive.

Positives

• Increasing authorized shares provides the company with greater flexibility for future capital raises, strategic transactions, and potential acquisitions, which are essential for growth.
• Expanding the 2023 Stock Incentive Plan is critical for attracting and retaining key talent, such as a Chief Medical Officer, ensuring the company can compete effectively in the industry.
• The proposed changes aim to align the company's capital structure and compensation practices with industry peers, enhancing its competitive position.
• Recent bonuses for the CEO ($293,150 annual, $200,000 special) and CFO ($156,400 annual, $150,000 special) were approved for efforts related to a recent capital raise and achievement of clinical/operational milestones, indicating progress.

Negatives

• The significant increase in authorized common stock from 100,000,000 to 500,000,000 shares creates substantial potential for future dilution of existing stockholders' voting rights, earnings per share, and book value per share.
• The increase in shares available for the incentive plan, while necessary for talent, also contributes to potential future dilution.

Risks

• Future issuance of additional shares of Common Stock or other convertible securities could dilute the voting rights, earnings per share, and book value per share of existing stockholders.
• The increase in authorized shares could potentially discourage or hinder efforts by other parties to obtain control of the Company, thereby having an anti-takeover effect.
• Failure to approve the 2023 Incentive Plan Amendment Proposal could lead to significant retention risk with employees, officers, non-employee directors, and other individual service providers if competitive equity-based compensation awards cannot be provided.
• Awards granted under the 2023 Incentive Plan are subject to clawback or recoupment policies and applicable laws.
• Certain tax implications, such as the alternative minimum tax for ISOs and potential limitations on company deductions under Section 162(m) of the Code, exist for equity awards.
• Indemnification provisions for directors and officers, while intended to attract talent, may discourage stockholders from bringing lawsuits for breach of fiduciary duties and could harm stockholders if the company pays settlement costs.

Future Outlook

The company anticipates increased working capital requirements and may need to raise additional capital through future equity financings. It plans to explore additional financing opportunities or strategic transactions that would require the issuance of additional shares of Common Stock, though no specific plans or negotiations are currently in existence. The company is also actively looking to hire additional personnel, particularly a Chief Medical Officer, to support operations and continued growth, with this process accelerated by a recent capital raise.

Management Comments

• The Board believes that the availability of additional authorized shares of Common Stock is required for several reasons including, but not limited to, the additional flexibility to issue Common Stock for a variety of general corporate purposes as the Board may determine to be desirable including, without limitation, future financings, investment opportunities, acquisitions, strategic transactions, or other distributions and stock splits.
• The Board also believes that the increase in our authorized Common Stock will help bring us more in line with our peers after the recent capital raise.
• The Board believes that the granting of stock options, restricted stock awards and similar kinds of equity-based compensation promotes continuity of management and increases incentive and personal interest in the welfare of our Company by those who are primarily responsible for shaping and carrying out our long-term plans and securing our growth and financial success.
• The current number of shares remaining available for grant under the 2023 Incentive Plan is insufficient for the purpose of providing equity-based compensation to attract and retain personnel.
• We may face significant retention risk with employees, officers, non-employee directors and other individual service providers if we are not able to provide competitive equity-based compensation awards.

Industry Context

Pasithea Therapeutics operates in the therapeutics/biotech industry, which is characterized by significant research and development costs, a need for substantial capital, and intense competition for highly qualified scientific and medical talent. The company's emphasis on increasing authorized shares for future financings and expanding its equity incentive plan reflects common industry practices for funding drug development and attracting specialized personnel, such as a Chief Medical Officer. Equity compensation is a standard and expected component of remuneration in this sector to align employee interests with long-term company success.

Comparison to Industry Standards

• The company states that the increase in authorized common stock will help bring it more in line with its peers after a recent capital raise, but does not specify which peers or provide comparative metrics.
• The Board determined that the current 2023 Incentive Plan does not provide sufficient share authorization for a duration comparable to that of equity incentive plans at similarly situated companies, indicating a need to match industry standards for talent attraction and retention.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a written related person transaction policy, reviewed and approved by the Audit Committee, covering transactions where the amount involved is the lesser of $120,000 or 1% of average total assets for the last two fiscal years.
• A consulting agreement with Prof. Lawrence Steinman (a non-employee director) was amended effective October 1, 2025, reducing quarterly payments from $25,000 to $1.00, in an effort to conserve cash. In recognition, Prof. Steinman received a one-time stock option award for 200,000 shares.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution of voting rights, earnings per share, and book value per share if the increased authorized shares are issued in future financings. However, the proposals aim to enable future growth and strategic opportunities that could ultimately benefit shareholders.
• **Employees, Officers, and Directors:** The expansion of the 2023 Stock Incentive Plan is intended to provide competitive equity-based compensation, crucial for attracting, motivating, and retaining high-quality talent, aligning their interests with the company's long-term success. Recent compensation adjustments and bonuses reflect efforts to reward performance and conserve cash.
• **Customers/Suppliers/Creditors:** No direct immediate impact mentioned, but successful future financings and talent acquisition enabled by these proposals could strengthen the company's ability to develop product candidates, potentially benefiting customers in the long term and ensuring stability for suppliers and creditors.

Next Steps

• Stockholders will vote on the Increase to Authorized Proposal and the 2023 Incentive Plan Amendment Proposal at the Special Meeting on January 28, 2026.
• If approved, the Certificate of Amendment to increase authorized shares will be filed with the Secretary of State of Delaware at a time determined by the Board to be most advantageous.
• If the 2023 Incentive Plan Amendment Proposal is approved, the company intends to file a registration statement on Form S-8 covering the additional shares.
• The company plans to hire additional personnel, particularly a Chief Medical Officer, to support operations and continued growth.

Key Dates

Recommendation

The proposals in this proxy statement are primarily procedural, seeking shareholder approval for capital structure flexibility and enhanced employee incentive programs. While the significant increase in authorized shares introduces a risk of future dilution, it is presented as a necessary step for a growth-oriented biotech company to pursue future financings, acquisitions, and attract critical talent. The expansion of the incentive plan is also vital for competitive talent retention in the industry. Given that this filing does not contain performance results but rather enabling actions, a 'hold' recommendation is appropriate. Investors should monitor the company's execution of its growth strategy and any subsequent capital raises, weighing the benefits of strategic flexibility against the potential dilutive effects.

Keywords

Pasithea Therapeutics, Proxy Statement, Authorized Shares, Stock Incentive Plan, Equity Compensation, Shareholder Vote, Dilution, Capital Raise, Corporate Governance, SEC Filing